Third Harmonic Bio, Inc. (THRD)

US — Healthcare Sector
Peers: SNSE  NXTC  NUVB  GRPH  MACK  CGEM  EWTX  RLYB  GLUE  PMVP  ENOB  RVMD  PASG  HOWL  ACRV  ELYM 

Automate Your Wheel Strategy on THRD

With Tiblio's Option Bot, you can configure your own wheel strategy including THRD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol THRD
  • Rev/Share 0.0
  • Book/Share 6.0694
  • PB 0.8584
  • Debt/Equity 0.011
  • CurrentRatio 54.0958
  • ROIC -0.2405

 

  • MktCap 235115817.0
  • FreeCF/Share -0.9283
  • PFCF -5.6387
  • PE -4.3785
  • Debt/Assets 0.0107
  • DivYield 0
  • ROE -0.1927

 

  • Rating B-
  • Score 3
  • Recommendation Neutral
  • P/E Score 1
  • DCF Score 4
  • P/B Score 4
  • D/E Score 4

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Downgrade THRD Stifel Buy Hold $23 $5 March 28, 2025
Downgrade THRD Morgan Stanley Overweight Equal Weight $20 $5 Feb. 12, 2025
Downgrade THRD Raymond James Outperform Market Perform -- -- Feb. 11, 2025

News

Third Harmonic Bio, Inc. (THRD) Upgraded to Buy: What Does It Mean for the Stock?
THRD
Published: February 14, 2025 by: Zacks Investment Research
Sentiment: Positive

Third Harmonic Bio, Inc. (THRD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Read More
image for news Third Harmonic Bio, Inc. (THRD) Upgraded to Buy: What Does It Mean for the Stock?
Third Harmonic Bio Initiates Strategic Review, Lays Off 50% Staff Citing Competitive Landscape
THRD
Published: February 12, 2025 by: Benzinga
Sentiment: Negative

On Tuesday, Third Harmonic Bio, Inc. THRD revealed results from its Phase 1 single and multiple ascending dose (SAD/MAD) trial of THB335 in healthy volunteers.

Read More
image for news Third Harmonic Bio Initiates Strategic Review, Lays Off 50% Staff Citing Competitive Landscape
Third Harmonic Bio Announces Phase 1 Clinical Results for THB335 and Provides Corporate Strategic Update
THRD
Published: February 11, 2025 by: GlobeNewsWire
Sentiment: Neutral

THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU) Company initiating process to leverage balance sheet strength to maximize shareholder value Cash and cash equivalents of approximately $285 million as of December 31, 2024 (unaudited) Management to hold conference call/webcast today Tuesday, February 11, 2025, at 8:00 a.m. EST to discuss clinical results and corporate next steps SAN FRANCISCO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced results …

Read More
image for news Third Harmonic Bio Announces Phase 1 Clinical Results for THB335 and Provides Corporate Strategic Update

About Third Harmonic Bio, Inc. (THRD)

  • IPO Date 2022-09-14
  • Website https://www.thirdharmonicbio.com
  • Industry Biotechnology
  • CEO Ms. Natalie C. Holles
  • Employees 31

Third Harmonic Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of the medicine for the treatment of allergic and inflammatory diseases. It develops THB001, an oral small-molecule KIT inhibitor for the treatment of chronic urticaria, a dermatologic disease driven by mast cell activation that results in red, itchy, painful welts, or hives, as well as for airway and gastrointestinal tract indications. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was founded in 2019 and is headquartered in Cambridge, Massachusetts.